Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Are They All the Same? A Narrative Review of Cardiovascular Outcome Trials
Sign Up to like & getrecommendations! Published in 2020 at "Diabetes Therapy"
DOI: 10.1007/s13300-020-00951-6
Abstract: Clinically important improvements in cardiovascular risk factors and adverse cardiovascular, heart failure and renal outcomes have been observed in numerous cardiovascular outcome trials (CVOTs) investigating the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors over the last… read more here.
Keywords: sglt2 inhibitors; sodium glucose; glucose transporter; cardiovascular outcome ... See more keywords
What have we learned about lipids and cardiovascular risk from PCSK9 inhibitor outcome trials: ODYSSEY and FOURIER?
Sign Up to like & getrecommendations! Published in 2019 at "Cardiovascular Research"
DOI: 10.1093/cvr/cvy301
Abstract: The role of proprotein convertase subtilisin/kexin Type 9 (PCSK9) in the regulation of the low-density lipoprotein (LDL)-receptor and plasma cholesterol was identified in 2003. This seminal discovery led to the rapid exploitation of PCSK9 as… read more here.
Keywords: learned lipids; lipids cardiovascular; cardiovascular risk; outcome trials ... See more keywords
Cardiovascular outcome trials in type 2 diabetes: A nurse practitioner perspective
Sign Up to like & getrecommendations! Published in 2018 at "Journal of the American Association of Nurse Practitioners"
DOI: 10.1097/jxx.0000000000000126
Abstract: ABSTRACT To provide an overview of cardiovascular outcome trials (CVOT) with once-weekly glucagon-like peptide-1 receptor agonists (GLP-1RAs), and other recent CVOTs, and to discuss the implications for the management of patients with type 2 diabetes… read more here.
Keywords: cardiovascular outcome; lowering drugs; type diabetes; outcome trials ... See more keywords
Improvement of glycemic control and reduction of major cardiovascular events in 18 cardiovascular outcome trials: an updated meta-regression
Sign Up to like & getrecommendations! Published in 2021 at "Cardiovascular Diabetology"
DOI: 10.1186/s12933-021-01401-8
Abstract: Background Besides providing reassurance about cardiovascular (CV) safety of newer diabetes drugs, cardiovascular outcome trials (CVOTs) have also shown encouraging benefits on some CV endpoints. The contribution of the better glycemic control in the reduction… read more here.
Keywords: reduction; mace; cardiovascular outcome; outcome trials ... See more keywords
Comment on Ferrannini and Rosenstock. Clinical Translation of Cardiovascular Outcome Trials in Type 2 Diabetes: Is There More or Is There Less Than Meets the Eye? Diabetes Care 2021;44:641–646
Sign Up to like & getrecommendations! Published in 2021 at "Diabetes Care"
DOI: 10.2337/dc21-0518
Abstract: I read with great interest the recent Perspective by Ferrannini and Rosenstock (1), which provides thoughtful insight on the interpretation of the numerous recent cardiovascular outcome trials (CVOT) in the field of type 2 diabetes.… read more here.
Keywords: cardiovascular outcome; leader; type diabetes; outcome trials ... See more keywords
Insulin Therapy and Cardiovascular Outcome Trials (Cvots): Any Harm, Anytime?
Sign Up to like & getrecommendations! Published in 2018 at "Genetics and Molecular Research"
DOI: 10.31031/gmr.2018.01.000513
Abstract: The therapeutic management of diabetes may on its own increase the risk of cardiovascular (CV) risk markers – directly or indirectly – through their pharmacological actions (e.g. side effects as hypoglycaemia), or some metabolic changes… read more here.
Keywords: therapy cardiovascular; insulin therapy; cardiovascular outcome; outcome trials ... See more keywords
A review of cardiovascular outcome trials in type 2 diabetes.
Sign Up to like & getrecommendations! Published in 2018 at "Endokrynologia Polska"
DOI: 10.5603/ep.2018.0053
Abstract: Type 2 diabetes is a complex metabolic disorder associated with a high risk of cardiovascular complications. In December 2008, due to concerns about the cardiac safety of antihyperglycaemic therapies, the Food and Drug Administration (FDA)… read more here.
Keywords: trials type; review cardiovascular; cardiovascular outcome; type diabetes ... See more keywords